Showing results (371-380 of 402) with videos related to

Sort By:
Pageof 41
Breast (Edinburgh, Scotland)|April 23, 2021
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trialHope S Rugo, Eduardo J Pennella, Unmesh Gopalakrishnan, et al.
Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.
Cancers|November 18, 2020
Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan TrialEleni Gkika, Stefan Lenz, Tanja Schimek-Jasch, et al.
Nature Microbiology|April 28, 2022
SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individualsJulia Lang-Meli, Hendrik Luxenburger, Katharina Wild, et al.
Annals of Hematology|October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IVLida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
JAMA|December 6, 2016
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical TrialHope S Rugo, Abhijit Barve, Cornelius F Waller, et al.
Msphere|September 8, 2021
A Prioritized and Validated Resource of Mitochondrial Proteins in Plasmodium Identifies Unique BiologySelma L van Esveld, Lisette Meerstein-Kessel, Cas Boshoven, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Breast Cancer Research and Treatment|June 14, 2021
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancerHope S Rugo, Eduardo J Pennella, Unmesh Gopalakrishnan, et al.
Pageof 41